News

Bimekizumab –⁠ Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?

12. 4. 2022 Source: Psoriasis

In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the first psoriasis treatment that selectively and directly inhibits interleukins IL-17A and IL-17F. It is intended for the treatment of moderate to severe plaque psoriasis in adults for whom systemic treatment is appropriate. The approval is based on three Phase III clinical studies in which bimekizumab demonstrated a very high rate of skin healing compared to placebo and active treatments like ustekinumab and adalimumab, as well as good tolerability.

Benefits of Enoxaparin Prophylaxis in Pregnancy and Postpartum

Study results suggest that the use of low molecular weight heparins during pregnancy could lead to better outcomes for women with thrombophilia and recurrent miscarriages. A group of authors from…

11. 4. 2022 Source: Thromboprophylaxis

Impact of Combined Oral Contraceptives on Body Weight

A relatively recent study investigated changes in the average body weight of women who used combined oral contraceptives with 30 μg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) or 30 μg EE and…

10. 4. 2022 Source: Oral Contraception

Monocyte Distribution Width as an Early Indicator of Sepsis in ICU Patients

Authors of a Franco-Spanish study propose using the monocyte distribution width along with leukocyte count as a screening test to refine the early diagnosis of sepsis in intensive care unit (ICU)…

9. 4. 2022 Source: Because

Curative Potential of Neoadjuvant Denosumab in the Treatment of Giant Cell Spinal Tumor? A Case Study

Portuguese authors present a case study of a young woman diagnosed with a giant cell spinal tumor who achieved complete histological remission following denosumab treatment.

9. 4. 2022 Source: Prevention of Bone Events

Prevention of Skeletal Events in the Therapy of Patients with Advanced Prostate Cancer

Prostate cancer most commonly forms metastases in the bones. In patients with this advanced disease, skeletal events occur, negatively affecting their quality of life. Zoledronic acid and denosumab…

9. 4. 2022 Source: Prevention of Bone Events

The Immune System in the Pathophysiology of ITP

From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.

9. 4. 2022 Source: Immune Thrombocytopenia

Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia

Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years.…

9. 4. 2022 Source: Immune Thrombocytopenia

Anticoagulation Therapy in Patients on ECMO During the COVID-19 Pandemic

In the past 2 years, the use of extracorporeal membrane oxygenation (ECMO) in intensive care units (ICU) has increased in connection with the treatment of severe COVID-19 pneumonia. Dr. Pilar Marcos…

8. 4. 2022 Source: Life-threatening Bleeding

Can Erdostein Help in Treating Infections Related to Biofilm Formation?

One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a…

8. 4. 2022 Source: Cough Therapy

hospitalizovaná pacienta covid nemocnice péče

Administration of Erdosteine After Severe Course of COVID-19 in the Early Period After Patient Discharge From Medical Facility

Erdosteine is a mucomodulatory drug used in the therapy of various acute and chronic respiratory diseases. Its mechanism of action is considered complex based on available evidence, encompassing…

8. 4. 2022 Source: Cough Therapy

1 … 56 57 58 59 60 … 115

Back Filter by speciality

Remove filters

Popular this week